drugset
Drugs / Adjuvanted H5N1 pandemic influenza vaccine
last change Mar 2019 re-read 3 minutes ago

Adjuvanted H5N1 pandemic influenza vaccine

also known as aH5N1c

Vaccine

Developed for
avian influenza
Investigated by
Department of Health and Human Services · Novartis Vaccines

Trials 2

today NCT01776541 · Ph 2 NCT01766921 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT01776541 Jan → Jun 2013 avian influenza Novartis Vaccines Completed Met primary
Phase 2 NCT01766921 Jan → Jul 2013 avian influenza Novartis Vaccines Completed Met primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Adjuvanted H5N1 pandemic influenza vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT01776541 ↗
1

NCT01766921 ↗
Known as aH5N1c “Methods: Two multicenter, phase II trials were conducted to evaluate the safety and immunogenicity of an MF59-adjuvanted, cell culture-derived, A/H5N1 vaccine (aH5N1c) among...” PMID 30968056 ↗ Mar 2019
Modality Vaccine “MF59-adjuvanted, cell culture-derived, A/H5N1 vaccine” PMID 30968056 ↗ Mar 2019